AI-Enabled Cardiac Imaging Revolutionizes Precision Angioplasty

 The Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) in Lucknow has introduced a cutting-edge AI-powered intravascular optical coherence tomography (OCT) system into its cardiology practice 

Why It Matters

Traditional angioplasty relies on manual interpretation of plaque images—a time-consuming and sometimes subjective process. The new AI-OCT system automates detection and analysis of arterial plaques in real-time, enabling cardiologists to optimize stent placement and tailoring treatment to plaque morphology.

First Clinical Successes

Already benefiting 15 patients, the system offers high-resolution 3D imaging with enhanced evaluation of coronary flow and plaque composition. Early reports emphasize clear advantages in accuracy, decision-making speed, and overall patient outcomes.




Expert Insight

SGPGIMS Director, Prof. R.K. Dhiman, emphasized the system’s potential to drastically improve outcomes for Indian patients, who often experience premature or severe coronary artery disease 

This suggests that the AI-OCT could become a new standard of care in plaque assessment and interventional cardiology. 

Blog Takeaways for Readers:

AI is advancing cardiology from theory to real-world precision tools.
AI-OCT systems offer unmatched real-time imaging and diagnostic support.
Personalized stent treatments may lead to better patient outcomes.
The shift to AI-driven angioplasty in India could inspire wider global adoption.

Do you think AI-assisted angioplasty will transform cardiology as we know it? Share your thoughts below!

To know more visit: https://www.cardiology.scientexconference.com/


Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more